MTOR and primitive neuroectodermal tumor: Although the median progression-free survival rate is 11 months for everolimus compared to 4.6 months with the placebo, most of the patients develop drug resistance indicating there is a void in our understanding of the mechanisms of resistance to mTOR inhibition in PNET.